KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.06
+3.75%Year over year
Reported trailing growth
- Revenue
- -93.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -88.2%
- EBITDA
- -74.5%
- EPS
- —
Three-year CAGR
- Revenue
- +3920.3%
- EBITDA
- +150.3%
- EBIT
- +133.5%
- Net income
- +146.4%
- EPS
- +146.8%
- Free cash flow
- +165.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026